BACKGROUND: Recent studies have demonstrated the tremendous potential of epicardial fat volume (EFV) to predict obstructive coronary artery disease. We aimed to develop a new model to estimate pretest probability of obstructive coronary artery disease using traditional risk factors with coronary calcium score and EFV and compare it with proposed models in Chinese patients who underwent coronary computed tomography angiography.
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A
ccording to recent guidelines, [1] [2] [3] estimating pretest probability (PTP) based on Duke clinical score or updated Diamond-Forrester model (UDFM) is crucial in the initial evaluation of patients with stable chest pain (SCP) and suspected coronary artery disease (CAD). However, several investigations have found that determination of PTP by invasive coronary angiography (ICA)-based models dramatically overestimated the actual risk of obstructive CAD in populations with low prevalence. [4] [5] [6] [7] [8] Of note, a pragmatic and multicenter trial manifested that the actual prevalence of obstructive CAD on coronary computed tomography angiography (CCTA) was only 10.3%, although for all these patients noninvasive testing was indicated according to current guidelines. 9 Considering the limitations of traditional approach for PTP which partly account for the overuse of noninvasive testing in contemporary cardiology practice, several new models have been developed in patients referred to CCTA. 10, 11 However, some traditional risk factors exhibit weak associations with CAD, 10, 12 which may attenuate the efficiency and practicability of PTP models. Moreover, although addition of coronary calcium score (CCS) improves the diagnostic accuracy comprehensively, our previous work in a cohort of Chinese population demonstrated a dissatisfactory calibration of CAD consortium extended model (CCEM), especially in medium to high PTP subgroups. 4 Epicardial fat volume (EFV), another noninvasive imaging indicator measured on noncontrast cardiac CT (NCCT), has been suggested to predict the presence and severity of obstructive CAD. 13, 14 Further, current studies
show that EFV provides incremental but not redundant predictive value above traditional cardiovascular risk factors. [15] [16] [17] However, to date, no published models are available for clinicians to integrate this promising individual indicator into routine estimation of PTP.
Consequently, in the present article, we posited that EFV offered incremental predictive value above traditional risk factors and CCS. Our major hypothesis was that a parsimonious combination of traditional risk factors, CCS and EFV would allow for a user-friendly and robust approach to PTP of obstructive CAD. We tested these hypotheses in a CCTA-based cohort consisted of Chinese participants with SCP suggestive of CAD. We also validated the best PTP model and compared it with UDFM 18 and CCEM 10 in an internal validation cohort composed of patients who underwent CCTA and ICA and an external validation cohort with clinical outcome data.
METHODS
Participants
The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. The details of inclusion and exclusion criterion of derivation cohort have been described elsewhere. 4 In brief, 5743 patients who underwent CCTA for SCP indicative of obstructive CAD were recruited between 2014 and 2016 in Tianjin Chest Hospital, Tianjin, China. From March 2014 to March 2015, we enrolled 2844 patients from the Chinese People's Liberation Army General Hospital, Beijing, China as an external validation cohort using the same inclusion and exclusion criteria and then patients were followed up for clinical outcome. For each patient in external validation cohort, downstream diagnostic and therapeutic strategy after CCTA was developed according to clinical practice at local institution and guideline recommendations. 1, 2 This study was approved by the ethics committees of Tianjin Chest Hospital and the Chinese People's Liberation Army General Hospital and all participants gave informed consent.
Clinical Definitions
Classification of symptom was judged in the interview with every patient by 2 experienced cardiologists who were blinded to the results of blood and imaging testing. Interobserver disagreements were resolved by consensus. SCP symptoms were categorized as nonanginal chest pain, atypical angina, or typical angina as described previously. 19 Typical angina was defined as having 3 characteristics: (1) substernal discomfort of characteristic quality, (2) precipitated by physical exertion or emotion, and (3) relieved with rest or nitroglycerin within 10 minutes. Atypical angina was defined as having 2 of the 3 definition characteristics. Nonanginal chest pain was characterized as chest pain or discomfort that meets 1 or 0 of the 3 definition characteristics.
Hypertension was defined as blood pressure of ≥140/90 mm Hg or the use of antihypertensive medication. Hyperlipidemia was defined as total cholesterol of ≥220 mg/
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dL, low-density lipoprotein cholesterol of ≥140 mg/dL, fasting triglycerides of ≥150 mm/dL, or receiving treatment with oral lipid-lowering agents. Diabetes mellitus was defined as fasting glucose levels over 7 mmol/L or treatment currently with either diet, oral glucose-lowering agents or insulin. Smoking was defined as current smoking or smoking in past 6 months. Changes in resting ECG was defined as the presence of ≥1 mm depression in at least 2 adjacent leads.
Measurements of CCS and EFV
Details of CCS 4 and EFV 20 quantification have been described previously. In the NCCT data sets, 2 experienced observers, a radiologist and a cardiologist, who were blinded to the clinical data and CCTA results analyzed the image on dedicated semiautomated softwares from Siemens support. Interobserver disagreements were resolved by consensus. CCS of all coronary arteries was calculated as previously described by Agatston. 21 To determine a region of interest, the pericardium was manually traced from the right pulmonary artery to the diaphragm. EFV was calculated as the sum of all pixels within a window of −200 to −30 HU in the region of interest.
CCTA Examination Procedure and Image Postprocessing
All CCTA scans were performed with a second-generation dual-source CT scanner (Somatom Definition Flash, Siemens Medical Solutions, Forchheim, Germany). In brief, according to the established guideline 22 and institutional protocols, 4 a CCTA scan was performed with detector collimation of 2×128×0.6 mm, slice thickness of 0.6 mm, gantry rotation time of 280 ms, heart rate adaptive pitch of 0.2 to 0.5, tube current of 290 to 560 mAs/rotation and tube voltage of 80 to 120 kV. Three experienced observers, 2 radiologists, and a cardiologist, who were blinded to the clinical and NCCT-based data evaluated the CCTA images on a Syngo Multimodality workstation (Siemens, German). Interobserver disagreements were resolved by consensus. In image analyses, all segments ≥2 mm in diameter were identified and analyzed using the Coronary Artery Disease-Reporting and Data System. 23 Obstructive CAD was defined as present if a patient had at least one lesion with ≥50% diameter stenosis or any unassessable segments because of severe calcification at CCTA.
Internal Validation of Models in Patients Who Underwent ICA
Based on recommendations in current guidelines, clinical practice at local institution and results of CCTA, ICA was indicated and performed within 2 weeks after CCTA in 23% (1999/8587) of the whole population (both derivation and external validation cohort).
Written informed consent was obtained from each patient before ICA. ICA was attempted with a 6 French guiding catheter through the radial or femoral artery. The angiographic images were acquired with a GE INOVA-2000 single-plane system at a cine rate of 30 frames/s. A minimum of 8 projections were obtained (minimum of 5 views for the left coronary artery system and minimum of 3 views for the right coronary artery system) and were evaluated by 2 experienced cardiologist who were unaware of the CCTA results.
For each patient in this internal validation cohort, diagnostic performance of CCTA compared with ICA was determined with sensitivity, specificity, positive predictive value and negative predictive value using a 2×2 cross-tabulation model.
Follow-Up for Clinical Outcome in External Validation Cohort
For each patient, we recorded increased changes of prescription in CAD medications, including antiplatelet agents, anti-ischemic drugs (such as nitrates, β-blockers, and calcium channel blockers), lipid-lowering agents and renin-angiotensin-aldosterone system blockers. Also, all noninvasive and invasive imaging tests performed within 60 days after CCTA were identified through review of the electronic medical record. The 60-day cutoff was selected to identify any downstream diagnostic and therapeutic strategy that was likely attributed to CCTA results.
Follow-up information was obtained by phone call and physician visit at 6 and 24 months after CCTA. The major adverse cardiovascular event was composed of cardiac death, nonfatal myocardial infarction, and late coronary revascularization. All events were adjudicated via review of hospital records independently by 2 cardiologists who were blinded to the results of baseline testing in consensus.
Cardiac death was defined as any death caused by cardiac disease or for which no other cause could be found. Myocardial infarction was defined when at least 2 of the following 3 criteria were met: chest pain or equivalent symptom complex, positive cardiac biomarkers, or typical ECG changes. 5 Planned revascularizations after CCTA were not counted as events because patients could be referred to revascularization based on results of imaging testing. An unplanned revascularization is usually prompted by (1) unanticipated disease progression or (2) unsatisfactory improvement of symptoms after optimal medical therapy, both of which imply the strategies of diagnosis and treatment are inappropriate. However, given the design and data sources of the present study, we could not accurately identify whether a revascularization was planned or not. Thus, on the basis of practice patterns in our centers, the usual nature history of stable CAD and other similar investigations, 5, 24 we defined late revascularizations (>60 days after CCTA) as unplanned ones and censored early ones (within 60 days after CCTA) to minimize verification bias. 5, 24, 25 For a late planned revascularization or an early unplanned revascularization, this can introduce subsequent biases, but both are infrequent.
According to results of CCTA, clinical outcomes, recommendations in recent guidelines 2 and the Coronary Artery Disease-Reporting and Data System, 23 the primary end point of this study was successful risk stratification, defined as following in each PTP category:
• In low PTP category, no or minimal CAD (diameter stenosis <25%) with no major adverse cardiovascular event during the entire follow-up period.
• In medium PTP category, increased changes of prescription in CAD medications or further testing attributed to CCTA results.
• In high PTP category, (1) ICA triggered by CCTA results or (2) no ICA but a major adverse cardiovascular event in the follow-up. 
Baseline Characteristics
Continuous variables were expressed as mean±SD. Student t test was used to compare normally distributed continuous data, and Mann Whitney U-tests was used to compare nonnormally distributed continuous data. Categorical variables were expressed as frequencies with percentages and differences in the percentages were compared using χ 2 test or Fisher exact test as appropriate. For simplicity, CCS and EFV were registered as categorical variables, based on the previous findings.
13,27
Development of PTP Models in Derivation Cohort
We defined 5 models: Model A=age+sex+angina+diabetes mellitus+hypertension+dyslipidaemia+smoking+ST-T change; Model B=Model A+CCS; Model C=Model A+EFV; Model D=Model A+CCS+EFV; Model E=age+sex+angina+CCS+EFV. Except for the noninvasive imaging indicators (CCS and EFV), traditional cardiovascular risk factors which were explicit to be associated with obstructive CAD 10, 12, 28 : age, sex, angina symptoms, hypertension, hyperlipidemia, diabetes mellitus, smoking, and changes in resting ECG, were included as candidate covariates. All univariate significant predictors were then included in a backward stepwise multivariate logistic regression analysis. Nonsignificant predictors with small effects (ie, odds ratio <1.01) in logistic regression were omitted. Additionally, clinical meaningful interactions between predictors were also considered. A nomogram was generated to illustrate the model with best performance. To maximize ease of clinical use, we also built a score by assigning points for each variable based on the relative importance of each variable as judged by the regression coefficient.
29
Sample Size
Sample size determination for observational study in multiple regression models is rather difficult. 26 We assumed that each cohort would have a prevalence of obstructive CAD of 30%. 4 In accordance with some empirical investigations suggesting to have at least 10 outcome events per variable for the derivation of a model 30 and at least 100 events for validation, 31 the minimum needed sample size was calculated at 334 in derivation cohort (10 candidate covariates) and 334 in validation cohort. Values are presented as n (%) unless stated otherwise. CAD indicates coronary artery disease; CCS, coronary calcium score; CCTA, coronary computed tomographic angiography; and EFV, epicardial fat volume.
*Obstructive CAD was defined as present if a patient had at least one lesion with ≥50% diameter stenosis or any unassessable segments because of severe calcification at CCTA.
Validation and Comparison of PTP Models
To evaluate calibration of a PTP model, we illustrated calibration plot and conducted Hosmer-Lemeshow goodness-of-fit test, 32 which is a measure of deviation between observed and predicted probability in deciles of PTP. To validate and compare PTP models, area under receiver-operator characteristic curve (AUC) compared by DeLong method, 33 integrated discrimination improvement (IDI quantifies the separation between estimated PTP of positive and negative individuals) 34 and net reclassification improvement (NRI quantifies the increase in PTP categories for positive individuals and the decrease for negative individuals) 34 were also calculated. For the assessment of NRI, a reclassification table was constructed using PTP categories <15%, 15%-85%, and >85% and the new model was compared with UDFM and CCEM, respectively. Those cutoff values were based on the 2013 ESC guidelines, 2 which states that noninvasive imaging testing for CAD have sensitivities and specificities of ≈85% and patients with a PTP <15% or >85% should not be referred to noninvasive testing, and other guidelines shared similar views.
1, 3 The details of statistical methods used in 3 cohort were as follows: (1) AUC, Hosmer-Lemeshow goodness-of-fit test, NRI and IDI were used for comparisons between new models in derivation cohort, (2) AUC, NRI, and IDI were used in internal validation cohort to compare and validate model E and UDFM, and (3) in external validation cohort, Hosmer-Lemeshow goodnessof-fit test, AUC, NRI, and IDI were used. Table 1 shows the distribution of baseline characteristics according to the presence of obstructive CAD in 2 study cohorts. The derivation cohort consisted of 5743 consecutive patients, of whom 1872 (33%) were found to have obstructive CAD on CCTA. The mean age was 57 years and 2986 (52%) were men. All variables were significantly associated to the presence of obstructive CAD (P<0.05). Among 2844 patients in the external validation cohort, 942 patients had obstructive CAD and these patients were older and had a higher proportion of men, smokers, angina, CCS >0, and EFV >100 mL (P<0.05). Compared with the external validation cohort, the derivation cohort comprised more patients with hypertension (45% versus 42%, P=0.0090), ST-T change (35% versus 53%, P<0.0001), nonanginal chest pain (36% versus 33%, P=0.0065) and fewer patients with typical angina (20 % versus 23%, P=0.0015). Table 2 summarizes the results of univariate and multivariate logistic regression. Age, sex, angina, hypertension, diabetes mellitus, hyperlipidemia, smoking and ST-T change, CCS, and EFV >100 mL were univariate significant predictors of obstructive CAD. Model A retained all candidate predictors, where addition of CCS and EFV >100 mL simultaneously decreased the effects of the other predictors resulting in the exclusion of hypertension and hyperlipidemia in model D. In model B, CCS was a major predictor and improved the fit. However, addition of EFV >100 mL alone did not promote the calibration in model C. The interaction terms were not included in the final model as they did not improve the model fit.
RESULTS
Baseline Characteristics
Development of New Models in Derivation Cohort
Comparison of New Models in Derivation Cohort
The receiver-operator characteristic curves of 4 new models are shown in Figure 1 In Table 3 
Validation and Comparison of Model E with UDFM in Internal Validation Cohort
Among patients who underwent CCTA and ICA, 79% (1580/1999) patients had positive CCTA and 73% (1457/1999) patients had obstructive CAD using ICA as reference standard. CCTA correctly identified obstructive CAD in 1434 patients, resulting in a sensitivity of 97% and a negative predictive value of 96%. On the other hand, CCTA correctly identified 396 in 542 patients without obstructive CAD by ICA, resulting in a specificity of 73% and a positive predictive value of 90%. Remarkably, false positive value of CCTA was 146 and false negative was 23 . More details about the baseline characteristics for patients who underwent ICA versus patients who did not are presented in Table 1 in the Data Supplement.
In Table 2 in the Data Supplement, the discrimination of model E was excellent with a positive IDI compared to UDFM (0.13; P<0.0001). The AUC for model E was significantly larger than that for UDFM (0.783 versus 0.732; P<0.0001). Table 3 in the Data Supplement shows the reclassification table in the ICA-based internal validation cohort. Compared to UDFM, the NRI for model E was 0.2232 in negative, 0.2718 in positive, and 0.4950 overall (P<0.0001).
Validation and Comparison of Model E With Proposed Models in External Validation Cohort
In Table 4 , the discrimination of model E was excellent, with an AUC of 0.853 and a positive IDI compared to UDFM (0.30; P<0.0001) or CCEM (0.09; P<0.0001).
The calibration plot for model E is presented in Figure 2. Calibration of model E was good, without statistically significant differences between predicted and observed probability (H-L Chi-square statistic=14.82; P=0.0626). Table 5 shows the reclassification table comparing model E to UDFM and CCEM, respectively. Of the 1902 negative patients, compared to UDFM, model E correctly reclassified 749 from medium to low PTP category, 87 from high to low and 153 from high to medium, but 48 from low to medium and 4 from medium to high. Of the 942 positive patients, 342 were correctly reclassified to a higher PTP category but 9 to a lower PTP category. As a result, compared to UDFM, the NRI for model E was 0.4927 in negative, 0.3536 in positive, and 0.8463 overall (P<0.0001). In other words, the replacement of UDFM by model E for every 2844/(749+87+153+11+278+53)≈2 patients would result in a correct reclassification for 1 patient. The improvement was moderate when the analysis was applied to CCEM, with NRI as follows: 0.0678 for negative, 0.0531 for positive, and 0.1209 overall (P<0.0001). Similarly, for each patient reclassified correctly, 2844/(143+5+8+5+6+52)≈13 replacements of CCEM by model E were needed.
Clinical Outcome in External Validation Cohort
Two hundred and fifty-seven of 2844 patients (9.0%) were lost on follow-up, and the median follow-up time was 2.7 years (IQR 1.9 to 3.3 years). MACE occurred in 138 patients (5.3%), including 9 patients (0.3%) died from cardiac cause, 28 patients (1.1%) suffered from nonfatal MI, 101 patients (3.9%) required late revascularization. The details of events are presented in Table 4 in the Data Supplement. Figure 1 in the Data Supplement shows the incidence of SRS in low, medium, and high groups classified by different PTP models. According to UDFM, the incidence of SRS was 73% (95% CI: 69%-77%) in low PTP group, 58% (95% CI: 53%-63%) in medium PTP group, and 49% (95% CI: 45%-53%) in high PTP group, respectively. Notably, compared to UDFM and CCEM, model E significantly (P<0.0001) improved risk stratification by increasing the incidence of SRS to 88% (95% CI: 86%-90%) in low, 85% (95% CI: 82%-87%) in medium, and 94% (95% CI: 92%-96%) in high PTP group, respectively. Table 5 in the Data Supplement provides more details about SRS in PTP groups according to different models.
Nomogram for Model E and CASES Score
At last, to facilitate clinical application of model E, an intuitionistic and accurate score manifested as a nomogram is created in Figure 3 , with a total of 13 points yielding a PTP <0.15 and 24 points yielding a PTP <0.85, classifying the individual into medium PTP group based on the cutoff value (0.15-0.85) selected in the present study. We also built a more convenient form, CASES AUC indicates area under the receiver operating characteristic curve; CCEM, coronary artery disease consortium extended model; CCTA, coronary computed tomography angiography; IDI, integrated discrimination improvement; PTP, pretest probability; and UDFM, updated Diamond-Forrester method.
*A positive patient was defined as a patient had at least one lesion with ≥50% diameter stenosis or any unassessable segments due to severe calcification on CCTA. (Calcification, Age, Symptom, Epicardial fat and Sex), score for daily clinical practice in Table 6 in the Data Supplement.
DISCUSSION
In this study, we described that EFV significantly improved prediction of obstructive CAD above traditional risk factors and CCS. We demonstrated that quantification of CCS and EFV in NCCT, combined with age, sex, and chest pain characteristics, allowed an accurate estimation for PTP of obstructive CAD. Compared with proposed models, the new model manifested more satisfactory discrimination, classification, and calibration in both a CCTA-based external validation cohort and an ICA-based internal validation cohort. What is more, it offered a more precise risk stratification to optimize decision-making of downstream diagnosis and treatment. These findings provided strong evidence that a simple strategy including the promising indicators from NCCT might improve diagnostic management of SCP among Chinese individuals. Current guidelines uniformly recognize the estimation for PTP of obstructive CAD as an essential component to address further diagnostic assessment. [1] [2] [3] Nonetheless, in recent large randomized trials and registry databases, 9, 24, [35] [36] [37] it has been suggested that the results of numerous noninvasive testing for patients with SCP were negative and the vast majority of such patients would not experience clinical events even during years of follow-up, implying that the traditional ICA-based approach for PTP revealed a markedly overestimation in patients referred for noninvasive imaging. 5, 6 In accordance with these findings, the present study, as well as the previous research completed by our team showed a low prevalence of obstructive CAD in symptomatic patients referred to CCTA, a dissatisfactory performance of UDFM 4 and a low rate of clinical events during follow-up.
Given substantial concerns about inappropriate clinical decision-making guided by erroneous risk assessments, several new PTP models have been developed in patients referred to noninvasive imaging. 10 ,11 CCEM represented a seminal achievement to build the foundation of the estimation for PTP using noninvasive imaging cohort and indicator, CCS. 10 Two external validation study also demonstrated that combining CCS with traditional risk factors significantly improved the prediction of obstructive CAD, 4, 6 which was confirmed by the larger AUC, better calibration, positive NRI and IDI of model B compared with model A in this article. In the meantime, several studies also indicated a sequential testing algorithm incorporating CCS with CCTA offered an effective and safe diagnostic strategy for SCP with potential benefits based on cost-efficiency. 25, 38, 39 Given all the evidence above, applying CCS as a gatekeeper can provide incremental value for quantitative risk assessment to guide clinical practice in patients with suspected CAD owing to SCP. 3, 27 Notwithstanding the aforementioned superiority of CCEM and CCS in the initial evaluation of SCP, several issues require attention. First, it has been demonstrated that in combination with CCS, demographic risk factors failed to significantly influence the prediction of CAD 5, 10, 12 and their identification and measurement may be imprecise and inconsistent in different researches and clinical settings. 4, 35 Second, although CCS actually detects and measures subclinical atherosclerosis, it does not seem to adequately reflect a substantial portion of the risk attributable to traditional risk factors, such as dyslipidemia. 40, 41 Third, the association between CCS and obstructive CAD has been the subject of debate across the spectrum of PTP. 42, 43 Among patients with medium to high PTP, CCS alone would neither exclude obstructive CAD nor predict its presence. 17, 44, 45 This was supported by 2 external validation studies that demonstrated a dissatisfactory calibration of CCEM in medium to high PTP subgroups, 4, 6 which might cause overuse of ICA according to current guidelines.
It has become evident that epicardial fat is far more than simply a fat storage depot surrounding coronary arteries, but rather a biologically active organ that influence coronary atherosclerosis development through endocrine and paracrine pathways. 46, 47 However, in most CCTA-based studies, although a critical and independent association of EFV with obstructive CAD has been demonstrated, [15] [16] [17] the relevant improvement of risk prediction resulting from addition of EFV is indeterminate. In the present study, we introduced this newer imaging marker into PTP models, resulting in a better discrimination and stratification (model D versus model B). This supported the hypothesis that EFV complemented diagnostic information of CAD through a mechanism different from CCS, such as lipid-rich plaque burden. What is more, once NCCT is performed for quantification of CCS, EFV is readily available without additional radiation exposure and contrast media application, which may ultimately promote the potential clinical implications of EFV. Some other new makers, such as peripheral arterial disease, inflammatory biomarkers, and carotid intima-media thickness and plaque also have been demonstrated to predict the presence of CAD, but neither do they provide superior prediction compared with CCS, 48, 49 nor can they be detected on NCCT, which is achieved with radiation exposure of <1 mSv, low cost, and no intravenous contrast material.
We developed model E incorporating 2 promising makers (CCS and EFV) from one cost-effective imaging modality (NCCT) into the most original and simple PTP system (age, sex, and symptom). Compared with model D, model E manifested no statistically difference in AUC, NRI, or IDI, indicating that this parsimonious constitute strategy offered a robust approach to PTP. Of note, in the external validation cohort, reclassification table for model E and UDFM revealed that for each individual reclassified correctly, only 2 additional NCCTs were needed to measure CCS and EFV. Similarly, when we replaced CCEM by model E, attached measurement of EFV based on completed NCCT for only 13 individuals would result in 1 correct reclassification with no extra diagnostic expenses and radiation exposure, and freedom from investigation of medical history and blood tests. What is more, model E optimized risk stratification by dramatically increasing the incidence of successful risk stratification in all PTP groups. Thus, decision-making of downstream diagnosis and treatment guided by this user-friendly and cost-effective model is an attractive strategy for contemporary cardiology practice, in consideration of the low yield of testing and the rising cost in current cardiovascular health care. 9, 24, 35, 36, 50 In term of the operability and reproducibility for model E in daily clinical practice, we provided a nomogram and a simpler form, CASES score.
Several issues of the present study merit consideration. First of all, although we developed the new model in a regional cardiovascular center recognized as tertiary A level and conducted external validation in a nonoverlapping cohort from a national medical center, this study was subjected to all of the limitations of its retrospective and observational design. For example, the indication of CCTA was based on individual physician decision, so a relevant number of patients with SCP have been scheduled for other tests, which incurred substantial biases. What is more, patients in the external validation cohort were followed up without extra intervention. Although we defined successful risk stratification according to guideline recommendations, results of CCTA and clinical outcome, given some nonmedical factors that affect practice patterns such as patients' expectations and financial incentives, the actual impact of applying PTP models in decision-making of clinical practice was complicated. Thus, the strategic discordance of downstream diagnosis and treatment after CCTA should not be ignored. In addition, the prediction capability of PTP models may be influenced by ethnic heterogeneities and distinct risk profiles in different regions. 4, 35 Generalizability and reliability of this attractive strategy for estimation of PTP need further investigations, such as pragmatic and cost-effectiveness randomized trials with comprehensive comparison of multiple strategies in multiethnic and multicentric cohorts.
Second, our previous study has compared and validated proposed models in the derivation cohort suggesting that all were poorly calibrated and UDFM and Duke clinical score had comparable performance. 4 What is more, comparison between the new and existing models in derivation cohort would likely overstate the added diagnostic value of EFV. Thus, although UDFM is a suboptimal reference comparator, we opted to compare the new model with UDFM and CCEM in an independent cohort to guarantee that the new strategy was primarily accounted for the improvement in prediction of obstructive CAD.
Third, given that our derivation and validation cohort were both CCTA or ICA-based, caution is needed about the generalizability of our results to a functional testing setting. However, Rozanski 36, 42 suggested that the potential using NCCT in conjunction with functional testing deserved more active consideration as a strong candidate for avoiding unnecessary diagnostic testing, because of the low cost and radiation exposure.
Fourth, the presence or absence of obstructive CAD can be misclassified by CCTA, especially in patients with high CCS because of artifacts caused by high-density calcification. 51 In the CCTA-based cohort, we defined unassessable segments due to severe calcification as positive ones, which was commensurate with guideline recommendations to further test when the calcification is severe. [1] [2] [3] On the other hand, we restricted the analysis to the subgroup of patients who underwent ICA. Although partly attenuated by the high prevalence of obstructive CAD in ICA-based cohort, improvements of AUC, IDI, and NRI ascribed to the addition of CCS and EFV stayed robust (Tables 5 and 6 ).
Fifth, allowing for easy interpretation, presentation, and operation in routine clinical practice, the 2 continuous variables commonly available from NCCT were transformed into categorical variables based on prior conclusions, 13, 27 which might lead to inadequate exploration and utilization of variables' predictive value.
Last, neither should these models be extrapolated to primary prevention in asymptomatic individuals, nor to the evaluation of acute chest pain settings. However, this NCCT-based strategy for risk assessment deserves further investigation in more fields.
In conclusion, this novel strategy for the assessment of PTP using 2 nonredundant markers measured on NCCT, CCS, and EFV, substantially improved the prediction of obstructive CAD in Chinese populations. Compared with proposed models, this user-friendly and cost-effective model might provide a more valuable tool to determine the optimal initial imaging modality.
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